Peripheral T-cell Lymphomas: Updates in Allogeneic Hematopoietic Stem Cell Transplantation.

The cumulative rate of 3-year OS and PFS rates was 64% and 53%, respectively.[ 13 ] Some studies about allo-HSCT for PTCLs showed a nonsignificant trend with better outcome in the population with AILT.[ 10 ] Twelve patients with advanced and refractory ENKL lymphoma, nasal type (ENKL) had undergone allo-HSCT, and seven cases were alive in sustained remission with a median follow-up of 13 months.[ 14 ] Only one case died of TRM during follow-up.[ 14 ] It is interesting to further clarify which subtype of PTCLs could be more susceptible to donor-derived immune cells.

also in 5,406 other papers